- H.C. Wainwright upgraded Celldex to a Buy rating, raising its price target to $64.00 from $42.00.
- The upgrade follows successful Phase 3 clinical trials for barzolvolimab, a drug targeting a chronic skin condition.
- Celldex is preparing for a 2027 FDA submission, highlighting significant progress in its drug development pipeline.
Celldex Therapeutics (NASDAQ:CLDX) is a biotechnology company that develops therapies to treat specific diseases. It focuses on conditions where current treatments are not sufficient. The company’s work involves extensive clinical trials to test the safety and effectiveness of its potential new medicines before they can be approved for public use.
Analyst firm H.C. Wainwright maintains its Buy rating for Celldex. A “Buy” rating suggests the analyst believes the stock’s price will increase. The firm also raised its price target, which is the price they expect the stock to reach, to $64.00 from a previous target of $42.00.
This positive view follows Celldex’s announcement of successful results from its Phase 3 clinical trials for the drug barzolvolimab. As highlighted by GlobeNewswire, these studies, named EMBARQ-CSU1 and EMBARQ-CSU2, tested the drug on patients with a chronic skin condition whose symptoms were not well-controlled by antihistamines.
The trials met all their primary goals, showing that the drug provided rapid and lasting benefits. The studies involved nearly 2,000 patients across 43 countries. Following these results, Celldex is preparing for a 2027 submission to the FDA for approval, as reported by Benzinga. The FDA, or Food and Drug Administration, is the U.S. agency that approves new drugs.
At the time of the announcement, Celldex was trading at $33.86. The stock has a market capitalization, or total value, of approximately $2.25 billion. The day’s trading volume was over 9.07 million shares, showing a high level of investor activity.
